PGT-M vs. PGT-A: Single-Gene Disorders vs. Chromosomes

PGT-M and PGT-A are both forms of preimplantation genetic testing performed on IVF embryos, but they look for fundamentally different things. PGT-M screens embryos for a specific inherited single-gene disorder that runs in the family, while PGT-A counts chromosomes to find embryos with the correct number. The distinction matters because the reasons you would pursue each test, the technical challenges involved, and the decisions you face afterward are quite different, even though both involve removing a few cells from a developing embryo and analyzing the DNA.

What Each Test Actually Screens For

PGT-M targets known single-gene (monogenic) conditions. If you or your partner carry a mutation linked to cystic fibrosis, sickle cell disease, Huntington’s disease, or any of hundreds of other inherited disorders, PGT-M identifies which embryos inherited the problematic variant. The goal is to select embryos that are either completely free of the mutation or, in the case of recessive conditions, are healthy carriers who will not develop the disease.¹ PGT-M is inherently personalized: a genetics lab needs to know what specific mutation it is hunting for, which means a workup phase before the IVF cycle even begins.

PGT-A, by contrast, is not looking for any particular gene. It counts whole chromosomes to determine whether an embryo is euploid, meaning it has the normal 46 chromosomes. Embryos with missing or extra chromosomes (aneuploidies) are the leading cause of failed implantation, early miscarriage, and conditions like Down syndrome. PGT-A is typically offered to patients with advanced maternal age, repeated IVF failures, recurrent pregnancy loss, or severe male factor infertility.²

A useful way to think about the split: PGT-M asks “does this embryo carry the family’s specific disease?” while PGT-A asks “does this embryo have the right number of chromosomes to develop normally?” The questions are independent, which is why some patients end up doing both simultaneously.

Who Gets Which Test and Why

PGT-M candidates usually know before they walk into the fertility clinic that a genetic condition is in play. Maybe they already have a child with a genetic disease, or carrier screening revealed that both partners carry the same recessive mutation, or one partner has a dominant condition like myotonic dystrophy. These couples may not have any fertility problems at all; they turn to IVF specifically because it is the only way to test embryos before pregnancy.

PGT-A candidates are often already in IVF for fertility reasons. They may be older, may have experienced unexplained implantation failures, or may want to reduce the chance of miscarriage. The test is sometimes presented as an add-on to improve IVF efficiency by avoiding the transfer of chromosomally abnormal embryos. Whether PGT-A actually helps in every age group is one of the more heated debates in reproductive medicine right now.

How the Lab Work Differs

Both tests start the same way. Around day five or six after fertilization, when the embryo has reached the blastocyst stage, a few cells are removed from the trophectoderm, the outer layer that will eventually become the placenta. The embryo is then frozen while the biopsied cells go to a genetics laboratory. What happens next in the lab, though, depends on the test.

For PGT-A, the analysis is relatively straightforward in concept. The lab uses next-generation sequencing or a similar platform to count chromosomal copies across the genome. An embryo with 46 chromosomes gets labeled euploid; one with 45 or 47 gets labeled aneuploid. Some embryos fall into a gray zone called mosaic, where the biopsied cells show a mixture of normal and abnormal chromosome counts.

PGT-M requires a more targeted approach. The lab needs to track whether a specific mutation was passed to the embryo, often by examining the DNA sequences surrounding the mutation and tracing which parental chromosome was inherited. This haplotype-based strategy is necessary because working with just a handful of cells creates a risk of allele dropout, where one copy of a gene simply fails to amplify during testing. If the disease-causing allele drops out, the embryo could be misdiagnosed as unaffected.³ Labs guard against this by using flanking markers such as short tandem repeats or single-nucleotide polymorphisms to confirm which parental chromosomes the embryo received.

Newer platforms are beginning to merge all forms of PGT onto a single sequencing run. One approach using whole-genome sequencing at relatively low depth achieved full concordance with traditional methods while simultaneously analyzing for aneuploidy, monogenic disease, and structural rearrangements from the same biopsy sample.⁴ These unified workflows are still newer but could eventually simplify combined testing and reduce costs.

The Allele Dropout Problem in PGT-M

Allele dropout deserves its own discussion because it is the signature technical vulnerability of PGT-M. When you are amplifying DNA from only a few cells, sometimes one of the two copies of a gene just does not get copied. If the missing allele happens to be the one carrying the disease mutation, the embryo looks healthy when it is not. If the missing allele is the normal one, the embryo might be wrongly classified as affected and discarded.

A large systematic assessment found that allele dropout occurred at about 11% of tested loci, spread across 70 different genes, and was detected in roughly a quarter of patients.⁵ The rate was lower with next-generation sequencing panels than with traditional Sanger sequencing, and the overlap between methods was minimal, meaning using both in parallel catches most of the dropout events that either alone would miss. This is why modern PGT-M protocols build in redundancy through linkage analysis rather than relying on direct mutation detection alone.

The Mosaic Embryo Problem in PGT-A

PGT-A has its own classification headache. Modern sequencing is sensitive enough to detect embryos where some biopsied cells look normal and others look aneuploid, a state called mosaicism.⁶ What to do with mosaic embryos has become one of the most contentious questions in the field. Some clinics consider them transferable with counseling; others treat them almost like aneuploid embryos and set them aside.

Part of the controversy stems from how representative the biopsy actually is. A handful of trophectoderm cells may not reflect what is happening in the inner cell mass, the part that becomes the baby. There are documented cases of mosaic embryos producing healthy pregnancies, and ongoing debate about whether some aneuploidies can self-correct as the embryo develops.⁷ For patients with few embryos, the mosaic question can be agonizing: do you transfer an embryo with uncertain chromosomal status, or do you go through another retrieval cycle?

Does PGT-A Actually Improve Live Birth Rates?

This is the question that stirs the most debate. The answer depends heavily on who the patient is. For women 38 and older, PGT-A appears to offer real advantages. One study found that patients in this age group who used PGT-A had a one-year cumulative live birth rate of about 51% compared with 36% for those who did not, along with fewer miscarriages and fewer transfers needed to get there.⁸ In high-risk patients with advanced maternal age, PGT-A also dramatically reduced biochemical pregnancy losses compared with controls.⁹

For younger patients, the picture is murkier. That same study found that women under 38 had almost identical one-year live birth rates whether or not they used PGT-A (about 70% vs. 67%).¹⁰ A large analysis of over 133,000 IVF cycles reported to the Society for Assisted Reproductive Technology found that PGT-A was associated with a reduced cumulative live birth rate at all ages 40 and under, partly because some patients lose their only embryos to an aneuploid result and have nothing left to transfer.¹¹ On the other hand, among patients who did have at least one euploid embryo to transfer, cumulative live birth rates were very high, ranging from about 71% in women under 35 to about 50% in women over 42.¹²

PGT-A consistently reduces miscarriage rates and multiple pregnancies across age groups, so even when overall live birth rates are similar, the experience of getting to a live birth can be less physically and emotionally grueling. Whether that trade-off is worth the added cost and the risk of having no transferable embryos is a personal calculation that depends on age, ovarian reserve, and how many embryos you expect to produce.

How Effective Is PGT-M at Preventing Genetic Disease?

PGT-M has a more straightforward success metric: did the baby end up free of the targeted condition? In that respect, accuracy rates are very high when modern linkage-based protocols are used. A study focused on hereditary neurological and metabolic disorders found a clinical pregnancy rate of about 74% per transfer and a live birth rate of roughly 89% among those pregnancies, with all resulting children born unaffected.¹³

A larger single-center study tracking 572 IVF cycles with PGT-M reported clinical pregnancy and live birth rates per transfer of about 51% and 45%, respectively.¹⁴ The gap between those two studies reflects the reality that PGT-M outcomes vary with the specific disease being tested, the patient population, and the clinic. What both share is the core finding that PGT-M is highly effective at preventing the birth of a child with the targeted condition.

The limiting factor for PGT-M is often the number of usable embryos. Only a fraction of embryos will be unaffected by the genetic condition, and of those, not all will be chromosomally normal or develop well enough for transfer. One study on neurological disorders found that only about 12% of embryos were ultimately transferable after PGT-M.¹⁵ This attrition is something patients undergoing PGT-M need to plan for, especially if they also add PGT-A.

Combining PGT-M and PGT-A in a Single Cycle

When couples doing PGT-M also want to screen for chromosome problems, both tests can be run from the same biopsy. This is increasingly common, but the math gets unforgiving. Each additional screening criterion eliminates more embryos. In one study, among embryos that passed PGT-M and were eligible for transfer, only about 49% were then found to be euploid when PGT-A was added. Twelve of the 44 patients ended up with no euploid embryos to transfer at all.¹⁶

The challenge intensifies when the family carries mutations in two different genes. In patients under 35 testing for variants in two genes, the likelihood of having at least one usable embryo dropped to 75% compared with about 83% when only one gene was being tested. The gap narrowed and became statistically insignificant in older age groups, likely because age-related aneuploidy already filters out so many embryos that the additional gene constraint makes less relative difference.¹⁷

Reassuringly, a multicenter study found that adding PGT-M to a PGT-A cycle did not change the proportion of euploid embryos: after adjusting for maternal age, euploid rates were essentially the same whether or not PGT-M was also being performed.¹⁸ In other words, PGT-M is not somehow damaging embryos or skewing chromosome results. The lower yield of transferable embryos is purely a numbers game: you are filtering the same pool through more criteria.

Biopsy Timing and Embryo Quality

Because both tests require a trophectoderm biopsy, the timing of that biopsy matters for outcomes regardless of which test you are running. Embryos biopsied on day five of development had higher live birth rates than those biopsied on day six, at least for good-quality blastocysts. One study reported live birth rates of about 74% for good-quality embryos biopsied on day five versus roughly 51% for similar-quality embryos biopsied a day later.¹⁹ For fair or poor-quality embryos, the day of biopsy did not make a significant difference.

Another variable is whether the blastocyst has begun hatching from its outer shell at the time of biopsy. Embryos biopsied before hatching had higher initial pregnancy rates, lower early pregnancy losses, and better live birth rates than those biopsied after spontaneous hatching began. The live birth gap was about five percentage points, and researchers suggested that biopsy may cause more damage to an embryo that is already in the vulnerable process of hatching.²⁰ These findings apply equally to PGT-M and PGT-A, since the biopsy procedure is the same.

The Cost Question

PGT adds thousands of dollars to an already expensive IVF cycle, and the cost-effectiveness picture is not straightforward. An economic analysis of PGT-A in women of advanced maternal age found that the test increased the cost per live birth by roughly 15% to nearly 285%, depending on assumptions about the base cost of IVF. The researchers calculated that PGT-A would need to boost pregnancy rates by at least 6% or be significantly cheaper than current pricing to break even. The cost to prevent one miscarriage through PGT-A came out to somewhere between about $34,000 and $51,000.²¹

PGT-M cost analyses are less commonly published, probably because the calculus is different. Families pursuing PGT-M are usually trying to avoid a specific, often severe genetic condition. The comparison is not just “IVF with testing versus IVF without” but also includes the costs of prenatal diagnosis, potential termination, or raising a child with a serious chronic disease. Many families and insurers view PGT-M as medically necessary in a way that PGT-A often is not, which affects insurance coverage in some health systems.

PGT-SR and the Third Category

There is a third form of preimplantation genetic testing that sits between PGT-M and PGT-A conceptually. PGT-SR screens for structural chromosomal rearrangements such as translocations, inversions, or large deletions. Carriers of these rearrangements often have normal health themselves but produce a high proportion of embryos with unbalanced chromosomes, leading to recurrent miscarriage or failed implantation. The European Society of Human Reproduction and Embryology considers familial translocations one of the most common indications for PGT-SR.²² The lab techniques overlap significantly with PGT-A since both involve scanning the genome for chromosomal imbalances, but PGT-SR requires additional resolution to distinguish balanced from unbalanced rearrangements.

Child Health After PGT

A reasonable worry for any parent is whether the biopsy itself or the genetic selection process harms the resulting child. The existing evidence, while still limited in volume, is reassuring. A study comparing children born after PGT with those born after standard IVF found no significant differences on most measures of general health and psychological well-being. Where differences did appear relative to population averages, the PGT children actually scored more positively on several outcomes.²³ The study’s authors cautioned that the sample was small and relied on parent-reported data, so larger and longer follow-ups are still needed. But nothing so far suggests that removing a few trophectoderm cells causes developmental problems.

HLA Matching and Saviour Siblings

One specialized application of PGT-M that raises distinct ethical questions is HLA typing for “saviour siblings.” In this scenario, a couple has a child with a condition like thalassemia or leukemia that could be treated with a stem cell transplant from an immunologically matched donor. PGT-M can be combined with HLA typing to select an embryo that is both free of the genetic disease and a tissue match for the sick sibling. The newborn’s umbilical cord blood then provides the transplant material.²⁴ Laws around the world vary widely on whether this is permitted. Some countries allow it with case-by-case ethical review; others ban it outright. The debate centers on whether selecting an embryo partly for the benefit of an existing child instrumentalizes the future child, balanced against the reality that the resulting baby is wanted and loved regardless of the transplant purpose.

Polygenic Embryo Screening

An emerging and controversial extension of preimplantation testing is PGT-P, which screens embryos not for a single gene or chromosome count but for polygenic risk scores associated with common diseases like heart disease, diabetes, or schizophrenia. Modeling studies have estimated relative risk reductions in the range of 15% to 35% for conditions in populations of European ancestry when selecting the lowest-risk embryo out of ten available. For non-European ancestries, particularly African, predicted risk reductions were substantially lower because the underlying risk-score models were developed mainly in European populations.²⁵ Even in the best case, absolute risk reductions are tiny for uncommon diseases, often less than half a percentage point. PGT-P is commercially available in some clinics but remains a subject of active scientific and ethical debate, with critics questioning whether the predictions are reliable enough to guide reproductive decisions.

Cross-Border Access and Regulatory Gaps

What types of PGT you can access depends partly on where you live. Some countries restrict PGT-M to a list of approved conditions, while others permit it for any known pathogenic variant. PGT-A regulation is similarly uneven: it is standard practice in the United States but more tightly regulated or less routinely offered in parts of Europe. These disparities drive a meaningful number of patients to seek treatment abroad. Research has documented that legal restrictions, cost differences, and perceived differences in clinic success rates all motivate cross-border reproductive care.²⁶ For patients considering PGT, understanding the regulatory environment in their country can save months of time and thousands of dollars.